University of Patras
Φαρμακοδυναμική και φαρμακοκινητική μοντελοποίηση για το μονοκλωνικό αντίσωμα της μπεβασιζουμάμπης σε ασθενείς με καρκίνο και συσχέτισή τους με κλινικά δεδομένα
Abstract
dc:descriptionABSTRACT Introduction This study focuses on patients with five different cancer types, breast, cervical, ovarian, lung and colon, who initially received various therapeutic regimens and subsequently continued with Βevacizumab as a maintenance monotherapy. Given the expanding use of Βevacizumab across diverse malignancies, the primary aim was to evaluate its pharmacokinetics and investigate its impact on clinical outcomes. Methods Conducted in collaboration with the University General Hospital of Patras “Panagia i Voitheia” and the Department of Pharmacy of the University of Patras, the study enrolled 89 patients who received Βevacizumab, either as monotherapy or in combination with other treatments. Serum samples were collected before and after drug administration for the measurement of Βevacizumab and VEGF levels via ELISA. Concentrations were compared across different treatment cycles and various cancer types, and a Cox proportional hazards analysis was employed to assess the relationship between Βevacizumab levels and disease progression. Results The mean peak concentration of Βevacizumab was 686.47 μg/ml, while the mean trough concentration reached 184.39 μg/ml. During treatment, a significant reduction in VEGF levels was observed, suggesting successful inhibition of angiogenesis. Patients receiving Βevacizumab monotherapy exhibited higher drug concentrations than those on combination regimens. In gynecological cancers, the most frequently reported adverse events were hypertension and paresthesia, while in other cancer types (e.g., lung), diarrhea and thrombosis were more common. Notably, prolonged control of VEGF was achieved without severe toxicities in most cases. Moreover, a distinct “critical point” was identified for each patient, beyond which therapeutic response declined, leading to relapse and emphasizing the importance of timely treatment modification. Conclusions Our findings confirm Βevacizumab’s efficacy in curbing VEGF levels and delaying disease progression across multiple cancer types. Notably, higher Βevacizumab doses appeared to boost therapeutic response but were linked to increased adverse effects—a pattern also reported in previous studies. This observation underscores the importance of rigorous drug-level monitoring, personalized dose adjustments, and vigilant patient follow-up. Identifying each patient’s specific threshold for diminishing returns can facilitate earlier therapeutic intervention and potentially improve clinical outcomes. Further large-scale research is needed to validate these results and deepen our understanding of Βevacizumab’s mechanisms of action. Keywords Βevacizumab, VEGF, pharmacokinetics, chemotherapy, viability, polymorphisms.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Liolis, Ilias
- Λιόλης, Ηλίας
Subjects
dc:subject × 11Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/59425